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OBJECTIVES: The Health Assessment Questionnaire (HAQ)
and the Modiﬁed HAQ (MHAQ) are examples of common
short-forms of physical function used to measure improvement
in the treatment of rheumatoid arthritis (RA) which have been
associated with ceiling problems. These problems, inherent to
short-form surveys, pose risks of failing to detect a treatment
response in clinical trials. Item Response Theory (IRT) methods
were used to examine the properties of two physical function
measures and construct a combined measure to better detect
changes in disease activity and treatment response. METHODS:
Data were from a 12-month, double-blind, multi-center study of
339 RA patients on a background of methotrexate randomized
to Abatacept at 2mg/kg, at 10mg/kg, or placebo. MHAQ and
SF-36 (with its Physical Functioning scale, PF10) were adminis-
tered at pretreatment and 3, 6, and 12 months post-treatment.
IRT methods were used to examine the surveys’ measurement
properties and compute new IRT-based physical function scores.
Analyses of variance were used to assess sensitivity to changes
in disease severity and treatment response. Relative validity coef-
ﬁcients were used to compare the measures. RESULTS: A Rasch
IRT model ﬁt the data. IRT-based scores successfully lowered the
ﬂoor and raised the ceiling of the physical function measured.
IRT-based scores were 30% more efﬁcient than MHAQ and
50% more efﬁcient than PF10 in discriminating among ACR
groups. In discriminating among treatment groups, IRT-based
scores were 25% more efﬁcient than MHAQ and 12% more efﬁ-
cient than PF10 at 6-months; and 16% and 17% more efﬁcient
at 12-months based on observed effect sizes. CONCLUSIONS:
Using IRT methodology to estimate a combined score for phys-
ical functioning lead to greater range of the construct measured.
The improved measure, with greater measurement precision and
sensitivity to treatment response, further conﬁrmed the beneﬁ-
cial effect of Abatacept on physical function in the treatment of
RA.
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OBJECTIVE: This study reassessed the psychometric perfor-
mance of the 11-item CSHQ-RA Short Form using a represen-
tative population of RA patients from 55 sites across the US.
METHODS: 307 of 309 screened patients from a 24-week mul-
ticenter, open-label, single arm study of RA patients receiving
anakinra completed the CSHQ-RA, the Medical Outcomes
Study Short Form-36 (MOS SF-36) and the Stanford Health
Assessment Questionnaire (HAQ) Disability Index. Data at
screening and baseline were used to examine the convergent
validity, discriminant validity, internal consistency, and test-retest
reliability. Convergent validity was tested, using Pearson’s cor-
relations, by comparing total score on the CSHQ-RA to those
from the Mental and Physical Component Summary (MCS and
PCS) of the MOS SF-36 and HAQ. ANOVA and Kruskal-Wallis
tests were used to assess the discriminant validity of the CSHQ-
RA. Internal consistency was measured by Cronbach’s alpha
coefﬁcient. Test–retest reliability was assessed using intraclass
correlation coefﬁcient (ICC). RESULTS: Response rate at base-
line was 95% (291). 81% of respondents were female; mean age
was 52 years (± 12); mean duration with RA was 10.8 years 
(± 10.4). Mean scores were CSHQ-RA Short Form 68.0 (± 16.0),
MCS 37.9 (± 10.9), PCS 31.2 (± 8.3), and HAQ 1.5 (± 0.7).
Pearson’s correlations with MCS, PCS, and HAQ were -0.69, 
-0.70, and 0.76 (P < 0.0001), respectively, demonstrating good
convergent validity. The difference in scores on the CSHQ-RA
Short Form of patients with different levels of physical disabil-
ity as measured by the HAQ was statistically signiﬁcant (P <
0.0001). Cronbach’s alpha coefﬁcient was 0.89, indicating good
internal consistency. Test-retest reliability was great with ICC
equal to 0.94. CONCLUSIONS: The results of this study
support the validity and reliability of the 11-item CSHQ-RA
Short Form as a measure that captures the impact of RA on
patients’ quality of life. Research to assess responsiveness and
clinically signiﬁcant change of the CSHQ-RA is under way.
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OBJECTIVES: Cox-2 selective inhibitors have been shown to
have similar efﬁcacy but a reduced gastrointestinal (GI) side-
effect proﬁle compared to non-selective non-steroidal anti-
inﬂammatory drugs (NSAIDs). The purpose of this study was to
use conjoint analysis (discrete choice methodology) to value the
reduction in risk of GI side effects with VIOXX (a Cox-2
inhibitor) when compared with non-selective NSAIDs in patients
with Osteoarthritis (OA). METHODS: Eighty-ﬁve participants
with OA were recruited for this project and asked to complete
questions regarding demographics, their OA and GI-related
symptoms and a discrete choice task. The attributes used in the
willingness-to-pay (WTP) scenarios included values for risks
associated with complicated perforations, ulcers and bleeds
(PUBs), uncomplicated PUBs, minor GI adverse and the cost of
medication to the patient. The risk estimates were derived from
clinical studies between VIOXX and non-selective NSAIDs.
RESULTS: Participants ranged in age from 49–83 years (mean
= 64.3 years). Twelve patients were excluded because they were
either non-traders (2) or irrational in their choice task (10),
leaving an effective sample size of 73. The total WTP for the
reduced risk of GI-complications provided by VIOXX, was
$A57.85 per month (95% CI:22.09–98.34). This included a
WTP of $A36.27 and $A38.43 for the reduced risk offered by
VIOXX of uncomplicated and complicated PUBs, respectively.
For minor GI events, the difference between the levels was not
statistically different from zero, indicating that no difference was
seen between the levels by the respondents. The point estimate
from this attribute produced a negative WTP (-$A16.85) that
